Product Description
● GLP-1R / GCGR Dual Agonism
Mazdutide targets both glucagon-like peptide-1 and glucagon receptors. This dual activity allows simultaneous regulation of glycemic control (via GLP-1R) and metabolic rate / energy expenditure (via GCGR).
● Long-Acting Design
The peptide is modified with a fatty diacid (C20) conjugated via a hydrophilic linker, which significantly increases its plasma half-life by promoting high albumin binding.
● Potent Biochemical Activity
- Human GCGR binding: Ki = ~17.7 nM; mouse GCGR: ~15.9 nM Biomol GmbH - Life Science Shop
- Human GLP-1R binding: Ki = ~28.6 nM; mouse GLP-1R: ~25.1 nM Biomol GmbH - Life Science Shop+1
- Stimulates insulin secretion in pancreatic islets: EC50 ≈ 5.2 nM (mouse) Biomol GmbH - Life Science Shop
● Metabolic Benefits Beyond Glucose Lowering
Beyond glucose control, Mazdutide’s GCGR activity supports increased energy expenditure, lipolysis, and improved liver fat metabolism. ChemicalBook+1
● Clinical Potential
Clinically, Mazdutide has shown significant body-weight reduction in human trials.
● Good Tolerability in Research Models
Preclinical and early human data suggest it is reasonably well tolerated. Reported side effects are primarily gastrointestinal (nausea, diarrhea) and heart rate increase, but these have been mostly transient and manageable.
| Parameter | Description |
| CAS Number | 2259884-03-0 |
| Product Name | Mazdutide (IBI-362; LY-3305677) |
| Molecular Formula | C₂₁₀H₃₂₂N₄₆O₆₇ |
| Molecular Weight | ~4,563.06 Da |
| Peptide Sequence | His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-{AEEA-AEEA-γGlu-Nonadecanoic acid}-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH₂ |
| Appearance | White to off-white lyophilized powder |
| Storage | ≤ –20°C, protected from light, dry |
| Specification | Option / Value |
| Purity | ≥ 98% (HPLC) |
| Form | Lyophilized powder |
| Vial Sizes | Typically 1 mg, 5 mg, 10 mg (depending on supplier) |
| Packaging | Sealed vials, moisture / oxygen control where needed |
| Shelf Life | ~24 months under recommended storage conditions (varies by provider) |
1. Obesity & Weight-Loss Research
Mazdutide is under investigation for obesity treatment, as its GLP-1R / GCGR dual mechanism can promote fat loss and reduce appetite while increasing energy expenditure.
2. Type 2 Diabetes (T2D) Studies
It is also used to model and study glycemic control, insulin secretion, and glucose metabolism in T2D, leveraging its GLP-1R activation and insulinotropic effects.
3. Liver Metabolism & NAFLD Research
Because glucagon receptor activation helps regulate liver fat metabolism, Mazdutide could be valuable in non-alcoholic fatty liver disease (NAFLD) or steatosis research.
4. Cardio-Metabolic Risk Investigation
Its effects on metabolic health (lipids, liver enzymes, body composition) make Mazdutide useful for studying cardio-metabolic risk factors in preclinical or translational research.
5. Novel Peptide Therapeutic Development
As a long-acting, receptor-biased agonist, Mazdutide provides a template for designing next-generation peptide drugs with dual receptor activity and improved pharmacokinetics.
